Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today provided program updates and announced financial results for the third quarter ended September 30, 2014. "Our Phase 2 PUMA study of PROHEMAA is approaching the second planned data safety review by the independent data monitoring committee.
http://ift.tt/1GP9lQG
http://ift.tt/1GP9lQG
No comments:
Post a Comment